XML 37 R17.htm IDEA: XBRL DOCUMENT
v3.23.1

Shareholders' Deficit | 3 Months Ended
--- | ---
Mar. 31, 2023
Equity [Abstract] |
Shareholders' Deficit | 10. Shareholders’ Deficit Changes in shareholders’ deficit for the three months ended March 31, 2023 and 2022 were as follows:
|  | Three Months Ended March 31, 2023 |
|  | Common Shares |  |  | Paid-in Capital in Excess of Par Value |  |  | Accumulated Other Comprehensive Loss |  |  | Accumulated Deficit |  |  | Total Shareholders’ Deficit |
|  | (in millions) |
Balance as of December 31, 2022 |  | $ | 0.1 |  |  | $ | 188.7 |  |  | $ | (250.2 | ) |  | $ | (1,204.5 | ) |  | $ | (1,265.9 | )
Issuance of 1.3 common shares from exercise of SARs, restricted stock units, employee stock purchase plan, and other |  |  | — |  |  |  | 0.5 |  |  |  |  |  |  |  |  |  | 0.5 |
Additional capital from share-based compensation |  |  |  |  |  | 10.8 |  |  |  |  |  |  |  |  |  | 10.8 |
Repurchases of 0.5 common shares |  |  | — |  |  |  | (8.7 | ) |  |  |  |  |  | — |  |  |  | (8.7 | )
Net income |  |  |  |  |  |  |  |  |  |  |  | 29.3 |  |  |  | 29.3 |
Foreign currency translation adjustment, net of income taxes of $— |  |  |  |  |  |  |  |  | 13.2 |  |  |  |  |  |  | 13.2 |
Unrealized loss on derivatives, net of income taxes of $— |  |  |  |  |  |  |  |  | (2.0 | ) |  |  |  |  |  | (2.0 | )
Balance as of March 31, 2023 |  | $ | 0.1 |  |  | $ | 191.3 |  |  | $ | (239.0 | ) |  | $ | (1,175.2 | ) |  | $ | (1,222.8 | )
|  | Three Months Ended March 31, 2022 |
|  | Common Shares |  |  | Treasury Stock |  |  | Paid-in Capital in Excess of Par Value |  |  | Accumulated Other Comprehensive Loss |  |  | Accumulated Deficit |  |  | Total Shareholders’ Deficit |
|  | (in millions) |
Balance as of December 31, 2021 |  | $ | 0.1 |  |  | $ | (328.9 | ) |  | $ | 318.1 |  |  | $ | (211.8 | ) |  | $ | (1,169.0 | ) |  | $ | (1,391.5 | )
Issuance of 1.0 common shares from exercise of SARs, restricted stock units, employee stock purchase plan, and other |  |  | — |  |  |  |  |  |  | 1.1 |  |  |  |  |  |  |  |  |  | 1.1 |
Additional capital from share-based compensation |  |  |  |  |  |  |  |  | 12.4 |  |  |  |  |  |  |  |  |  | 12.4 |
Repurchases of 3.0 common shares |  |  | — |  |  |  |  |  |  | (21.9 | ) |  |  |  |  |  | (94.3 | ) |  |  | (116.2 | )
Net income |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 98.2 |  |  |  | 98.2 |
Foreign currency translation adjustment, net of income taxes of $— |  |  |  |  |  |  |  |  |  |  |  | 4.4 |  |  |  |  |  |  | 4.4 |
Unrealized loss on derivatives, net of income taxes of $— |  |  |  |  |  |  |  |  |  |  |  | (2.6 | ) |  |  |  |  |  | (2.6 | )
Cumulative effect of accounting change relating to adoption of ASU 2020-06 |  |  |  |  |  |  |  |  | (136.7 | ) |  |  |  |  |  | 77.6 |  |  |  | (59.1 | )
Balance as of March 31, 2022 |  | $ | 0.1 |  |  | $ | (328.9 | ) |  | $ | 173.0 |  |  | $ | (210.0 | ) |  | $ | (1,087.5 | ) |  | $ | (1,453.3 | )
Dividends The Company has not declared or paid cash dividends since 2014. The declaration of future dividends is subject to the discretion of the Company’s board of directors and will depend upon various factors, including its earnings, financial condition, Herbalife Ltd.’s available distributable reserves under Cayman Islands law, restrictions imposed by the 2018 Credit Facility and the terms of any other indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by its board of directors. Share Repurchases On February 9, 2021, the Company’s board of directors authorized a new three-year $1.5 billion share repurchase program that will expire on February 9, 2024, which replaced the Company’s prior share repurchase authorization that was set to expire on October 30, 2023 and had approximately $7.9 million of remaining authorized capacity when it was replaced. This share repurchase program allows the Company, which includes an indirect wholly-owned subsidiary of Herbalife Ltd., to repurchase the Company’s common shares at such times and prices as determined by management, as market conditions warrant, and to the extent Herbalife Ltd.’s distributable reserves are available under Cayman Islands law. The 2018 Credit Facility permits the Company to repurchase its common shares as long as no default or event of default exists and other conditions, such as specified consolidated leverage ratios, are met. As of March 31, 2023, the remaining authorized capacity under the Company’s $1.5 billion share repurchase program was approximately $985.5 million. During the three months ended March 31, 2023, the Company did no t repurchase any of its common shares through open-market purchases. During the three months ended March 31, 2022, the Company repurchased approximately 2.6 million of its common shares through open-market purchases at an aggregate cost of approximately $101.7 million, or an average cost of $39.32 per share, and subsequently retired these shares. The number of shares issued upon vesting or exercise for certain restricted stock units and SARs granted pursuant to the Company’s share-based compensation plans is net of the statutory withholding requirements that the Company pays on behalf of its employees. Although shares withheld are not issued, they are treated as common share repurchases in the Company’s condensed consolidated financial statements, as they reduce the number of shares that would have been issued upon vesting. These shares do not count against the authorized capacity under the Company’s share repurchase program described above. During the three months ended March 31, 2023 and 2022, the Company withheld shares on its vested restricted stock units and exercised SARs relating to its share-based compensation plans. The Company reflects the aggregate purchase price of its common shares repurchased as an increase to shareholders’ deficit. The Company generally allocated the purchase price of the repurchased shares to accumulated deficit, common shares, and additional paid-in capital, with the exception of treasury shares, which are recorded separately on the Company’s condensed consolidated balance sheets. For the three months ended March 31, 2023 and 2022, the Company’s share repurchases, inclusive of transaction costs, were zero and $101.7 million, respectively, under the Company’s share repurchase programs, and $8.7 million and $14.5 million, respectively, due to shares withheld for tax purposes related to the Company’s share-based compensation plans. For the three months ended March 31, 2023 and 2022, the Company’s total share repurchases, including shares withheld for tax purposes, were $8.7 million and $116.2 million, respectively, and have been recorded as an increase to shareholders’ deficit within the Company’s condensed consolidated balance sheets. Accumulated Other Comprehensive Loss The following table summarizes changes in accumulated other comprehensive loss by component during the three months ended March 31, 2023 and 2022:
|  | Changes in Accumulated Other Comprehensive Loss by Component |
|  | Three Months Ended |
|  | March 31, 2023 |  |  | March 31, 2022 |
|  | Foreign Currency Translation Adjustments |  |  | Unrealized Loss on Derivatives |  |  | Total |  |  | Foreign Currency Translation Adjustments |  |  | Unrealized Loss on Derivatives |  |  | Total |
|  | (in millions) |
Beginning balance |  | $ | (248.2 | ) |  | $ | (2.0 | ) |  | $ | (250.2 | ) |  | $ | (211.6 | ) |  | $ | (0.2 | ) |  | $ | (211.8 | )
Other comprehensive income (loss) before reclassifications, net of tax |  |  | 13.2 |  |  |  | (4.7 | ) |  |  | 8.5 |  |  |  | 4.4 |  |  |  | (2.6 | ) |  |  | 1.8 |
Amounts reclassified from accumulated other comprehensive loss to income, net of tax(1) |  |  | — |  |  |  | 2.7 |  |  |  | 2.7 |  |  |  | — |  |  |  | — |  |  |  | — |
Total other comprehensive income (loss), net of reclassifications |  |  | 13.2 |  |  |  | (2.0 | ) |  |  | 11.2 |  |  |  | 4.4 |  |  |  | (2.6 | ) |  |  | 1.8 |
Ending balance |  | $ | (235.0 | ) |  | $ | (4.0 | ) |  | $ | (239.0 | ) |  | $ | (207.2 | ) |  | $ | (2.8 | ) |  | $ | (210.0 | )
(1) See Note 9, Derivative Instruments and Hedging Activities, for information regarding the location within the condensed consolidated statements of income of gains (losses) reclassified from accumulated other comprehensive loss to income during the three months ended March 31, 2023 and 2022.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI https://asc.fasb.org/topic&trid=2208762 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (g) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (h) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 16 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (i) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 50 -Paragraph 6 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration